Aboriginal and Torres Strait Islander adults without risk conditions for pneumococcal disease are recommended to receive:
a dose of 13vPCV or 15vPCV at age ≥50 years
a dose of 23vPPV 12 months later
a 2nd dose of 23vPPV at least 5 years later
This is based on:
the increased risk of pneumococcal disease in Aboriginal and Torres Strait Islander adults, compared with non-Indigenous adults
the high proportion of invasive pneumococcal disease caused by additional serotypes only in 23vPPV
Aboriginal and Torres Strait Islander adults who have previously received 23vPPV are recommended to receive:
1 dose of 13vPCV or 15vPCV 12 months after their last 23vPPV dose
1 dose of 23vPPV 12 months after their 13vPCV dose or 15vPCV, or 5 years after their previous 23vPPV dose, whichever is later. If they have already received at least 2 doses of 23vPPV, no further 23vPPV doses are recommended.
In all these scenarios, the interval between doses of 13vPCV or 15vPCV and 23vPPV should be 12 months, but 2–12 months is acceptable. The interval between doses of 23vPPV should be 5 years.
The Department of Health and Aged Care acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.